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A Simple Assay for Specific Estrogen Binding Capacity
in Human Mammary Tumours
By C. B. KORSTEN and j.-P. PERSIJN
From the Department of Clinical Chemistry (Head: Dr. J.-P. Persijn), Netherlands Cancer Institute, Amsterdam
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A simple method is described for the measurement of specific binding of estradiol by extracts of human mammary tumours or metastases.
The method, which is applicable to small samples, involves incubation of homogenate with labelled estradiol. As a control, specific binding
is abolished by preheating at 45—50°C, or the addition of a potent anti-estrogen (U 11, 100).
Free and bound estradiol are separated by charcoal.
Of 59 biopsies histologically verified as malignant, 41 were found to contain estradiol binding receptor.
Eine einfache Methode zur Bestimmung der spezifischen Bindung von östradiol durch Extrakte von menschlichen Mamrriätumoren oder
deren Metastasen wird beschrieben.
Die Methode ist für kleine Proben anwendbar. Das Homogenat wird mit radioaktiv markiertem Östradiol inkubiert. Als Kontrolle wird
auf 45—50° C erhitztes Homogenat verwendet oder Homogenat nach Zugabe eines hochwirksamen Anti-östrogens (Ü-ll. 100), das die
spezifische Bindung aufhebt.
Freies und gebundenes Östradiol werden mit Aktivkohle getrennt.
Von 59 histologisch als maligne gesicherten Biopsieproben wurde bei 41 der östradiol-bindende Rezeptor nachgewiesen.
It is now generally accepted, particularly through the
work of JENSEN et al (1, 2), that in the uptake of estro-
gens by cells of target organs, the hormone is bound
specifically to a cytoplasmic protein, which is called
"receptor".
The binding of estrogen to its receptor appears to be an
early but essential step in the mechanism of stimulation
of biosynthetic processes in cells of hormone-dependent
tissues. Several investigators (3, 4, 5) have observed that
some, but not all, human malignant breast tumours can
accumulate estrogens in vivo.
These findings are interesting in view of the clinical
observation that only some patients benefit from hormo-
nal therapy.
A link between the hormone dependency of breast
tumours and their ability to accumulate estrogens has
been noticed by FOLCA et al (3). These workers injected
tritium labelled estrogens into ten patients with breast
cancer shortly before they were submitted to adrenalec-
tomy. Biopsies of tumour tissue were taken and assayed
for their tritium activity. In four patients the concentra-
tion of tritium was higher then in muscle and only these
patients were benefiting from the therapy.
In later studies JENSEN et al (16) found evidence that
certain human breast tumours contain receptor pro-
teins.
If the presence of estrogen receptors determines the
hormone dependency of breast tumours, their' assay
might be of major importance in the choice of treatment.
The data gathered thus far (3, 6, 7) suggest that a routine
assay of the specific estrogen binding capacity (by
receptor) of tumours might provide a clinically valuable
parameter.
The assay of the estradiol binding receptor of the
tumour should be done in vitro rather than by in vivo
studies (8).
TERENIUS (7) incubated tissue slices in buffer containing
labelled estradiol. As a control, slices from the same
tumour were incubated in an identical medium to which
Upjohn 11, 100 had been added.
Upjohn 11, 100 is a potent anti-estrogen3 which sup-
presses specifically the binding of estrogens to receptor
proteins from rat target organs (2). The extent to which
the accumulation of radioactivity was suppressed by
Upjohn 11, 100 was considered to represent receptor
bound estradiol. It was found by this technique that
only some of the patients had tumours with estradiol
binding capacity.
The present paper describes a simple technique which
can handle a large number of samples. Tumours from
a number of patients (71) were assayed for estrogen
receptors in order to extend the available data.
Materials and Methods
Hormones
Tritium labelled estradiol-17/? (labelled in the 6,7 positions) with
a specific activity of 40 Ci/mole) was purchased from the Radio-
chemical Centre Amersham, England, the unlabelled estradiol-17/?
was obtained from the Sigma Chemical Company, St. Louis, USA.
Upjohn 11, 100 (l-[2-[p-(3.4-dihydro-6-methoxy-2-phenyl-l-
naphtyl) phenoxy]-ethyl]pyrrolidine HC1) was a gift from the
Upjohn Company, Brussels, Belgium.
Tumours
Tumour tissues (breast of biopsies from metastases in the skin)
were freed from fat as completely as possible. The tissues were
stored at — 90° C. This treatment does not significantly change the
binding capacity of the receptor for the estrogen (9).
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Tab. 1
Procedure for measurement of estrogen binding capacity (modified KORENMAN and DUKES technique)
Tube No.
Estradiol-170 (0.5 jumol/1)1)








0.5 ml 0.5 ml 0.5 ml 0.5 ml
let stand for 1 hour at 4°C.
__ _ 50//I 50 μ\
incubate 16 hours (4°C)
0.5 ml — — —









») in 0.01 mol/1 Tris buffer .pH 7.4 containing 0.0015 mol/1 EDTA and 0.25 mol/l sucrose
a) preheated at 45—50eC (1 hour)
Procedures
The assay of estrogen binding was carried out according to
KORENMAN and DUKES (10) with certain modifications: the homo-
genisation of the tissue was performed at low temperature as
described by WAGNER (11, 12). Another modification'was the use
of additional controls for the measurement of unspecific binding.
To control incubations containing labelled estradiol, Upjohn
11, 100 was added for competitive inhibition. The measurement of
the binding of labelled estradiol by homogenates which had been
treated for 1 hour at 45—50°C served as a second control. WAGNER
(10) found that preheating destroys the receptor protein binding
capacity.
Several tumours were assayed for estrogen binding capacity using
the electrophoresis technique of WAGNER (11, 12).
Preparation of extract
Tissue, still frozen, was pulverised in a porcelain mortar chilled
in liquid nitrogen. Two or three volumes Tris buffer (pH 7.5;
0.01 mol/1) were added to the mortar and the contents were
pulverised again. The powder was left to thaw. The homogenate
was centrif uged at 3000 rpm for 20 min at 4° C. The supernatant
was filtered (Schleicher and Sch ll 589/2).
Assay of binding capacity using the KORENMAN and DUKES technique
Table 1 summarizes the standard procedure. It should be noted
that tubes 3, 4, 5 and 6 were treated in duplicate. Bound and free
labelled estradiol were separated by centrifugation after the
addition of dextran coated charcoal. Tubes 1 and 2 serve as a control
for the removal of labelled estradiol by the charcoal suspension.
The latter was prepared according to KORENMAN and DUKES (10).
Aliquots (0.5 ml) of the supernatants were added to BRAY'S fluid
and counted in a liquid scintillation counter for the determination
of tritium activity.
Assay of binding capacity using electropboresis
The method of WAGNER separates estradiol bound to receptor
from free and unspecifically bound estradiol by means of electro-
phoresis (11,12). The homogenate was incubated with 2 nmol/13H-
estradiol-17jff at pH 7,5 (Tris buffer 0.01 mol/1) for two hours at 4°C.
After incubation the mixture was submitted to electrophoresis.
Preheated (1 hour at 45PC) homogenate was used as a control,
Electropboresis
The electrophoresis has been described in detail elsewhere (11, 12).
Briefly, a 5 mm thick layer of agar. on glass ( 9 x 9 cm) was pre-
pared from a 2% agar Noble solution in 0.05 mol/1 Veronal buffer.
At the centre 10 holes were punched, the diameter of which was
such that they could be filled with 50 μΐ of the test solution. Two
adjacent holes were filled with the same test solution. The glass
plate supporting the agar layer rested on a block of copper brass
the surface of which was maintained at — 10°C. Thermoelectric
measurements confirmed that the temperature in the agar did not
rise above -f 10° C during electrophoresis (2 hours, 80 m A). After
electrophoresis the agar layer was sliced in strips containing two
holes each. The strips were cut into 15 pieces lengthways. The
pieces were freeze-drycd and counted after burning in a Packard
sample oxidizer.
Results
Figures 1 —3 show the electrophoretic patterns of homo-
genates of three different histologically verified human
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Fig. 1
Electrophoretic pattern of extract of tumour No. 1 after incubation
with labelled »H-estradiol. Endosmotic flow moves unbound 3H-
estradiol and »H-estradiol released from unspecifically binding proteins
to the cathode. The receptor bound estradiol appears in the anodic
region. · - · tumour homogenate, ο ---- ο tumour homogenate
heated
1 2 3 4 5 6 7 8 9 10 11 12 13 Η 15
Froction number
Fig. 2
Electrophoretic pattern of extract of tumour No. 2 after incubation
with labelled "H-estradiol. · · tumour homogenate, ο ο tu-
mour homogenate heated
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Fig. 3
Ejectrophoretic pattern of extract of tumour No. 3 after incubation
with labelled 3H-estradiol. · - · tumour homogenate, ο ---- ο tu-
mour homogenate heated
estradiol receptor in the anodic region. Figure 1 refers
to a tumour possessing a high level and figure 2 to a
tumour with a moderate level of estradiol receptor.
Unbound excess of estradiol moves to the cathode which
permits separation of free and bound estradiol.
The albumin band is located before the receptor zone,
but the weakly bound estradiol is released from albumin
during the electrophoresis (11, 12).
Tumour 3 (fig. 3) shows only a large peak (unbound
estradiol-17jo) which appears at the cathodic side. The
curves for the preheated and unheated extracts coincide.
This tumour is considered to be receptor negative.
The results of the modified KORENMAN and DUKES
technique obtained with the tumours previously
described are listed in table 2. Estradiol bindings are
expressed as counting differences between the assay
using labelled estradiol without any additive or pre-
treatment and the control experiments. Tumours 1 and 2
show strong and moderate binding, respectively. Since
the counting difference using Upjohn 11, 100 is con-
sidered to give the most reliable measure for receptor
bound estradiol-17/?, tumour No. 3 could be inter-
preted as receptor negative. It will be noted that the
estradiol binding characteristics of tumours 1, 2 and 3
are in agreement with those obtained by the electro-
phoresis technique. The latter, however, is not capable
of handling a large number of samples within a short
time. In addition the material available is limited, which
Tab. 2
Effect of unlabelled estradiol (excess), Upjohn 11, 100 or preheating on
the binding of labelled estradiol by three tumour homogenates. These
homogenates were also examined for their binding of labelled estradiol
by agar gel electrophoresis (see fig. 1—3)
Tumour No. Bound 3H-estradiol
[counts/min]
with unlabelled excess with Upjohn 11, 100 after heating
1 1398 1356 1360
2 131 117 '85
3 20 10 —30
restricts both the number of tumours that can be in-
vestigated and the number of controls. The modified
KORENMAN and DUKES technique was chosen as a routine
method. The method is applicable to small (100mg)
samples which is useful for the study of metastases.
The electrophoresis technique remains highly attractive
for the study of fundamental problems e. g. binding
studies with several 'estrogen antagonists etc. The
quantitative aspects of the modified KORENMAN and
DUKES technique were studied using dilution experi-
ments. The results are depicted in figure 4. Table 3
shows counting differences between the assay using
8H-estradLoH7/? alone and the controls as obtained for
biopsies from human primary breast tumours or
metastases. Comparison of the amounts of radioactivity
in the presence of Upjohn 11, 100 shows considerable
resemblance to those obtained with excess unlabelled
estradiol. There are readily discernable differences
between results using Upjohn 11, 100 and those found
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Fig. 4
Relationship of spechically bound Ή-estradiol and concentration of
extract of mammary tumour. The different curves relate to the sup-
pressibility of bound 3H-estradiol by unlabelled excess (o-^--o) or













Chart of estrogen binding capacities of primary mammary tumours (·)
or metastases (o) (left and middle) and benign tumours (X, right) as
calculated from the control experiments using Upjohn 11, 100
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Tab. 3
Effect of u n labe I led estradiol (excess), Upjohn 11, 100 or preheating on the binding of labelled estradiol by tumour homogenates
(counts/ml n · g tissue)


















































































































































































































as good since the results of both assays follow the same
ranking order.
On preheating, some protein may undergo transfor-
mations resulting in an increased amount of unspeci-
fically bound estradioM?/?. This may explain the nega-
tive values (tables 2 and 3, third column). Additional
information is given in figure 5 which shows the
distribution of binding capacities obtained by using
Upjohn 11, 100 as a control.
The points inserted left in this figure refer to the tumours
listed in table 3. Additional data are given in the middle
part of figure 5. These data refer to predominantly post-
menopausal histologically verified breast tumours. The
area between ± 4,000 and 8,000 counts/min · g tissue,
which is characterized by the relative absence of points,
is considered arbitrarily as the separation of 'receptor-
negative', tumours from 'receptor-positive'. Thus, of
the 56 malignant tumours described in figure 5, 39
contain estradiol receptors. Table 4 summarizes results
obtained with benign breast disease. Of twelve cases, ten
are considered-to be 'receptor-negative* since they fall
below the 4,000 counts/min · g tissue borderline. The
data for the benign tumours, although limited to a small
number of cases are in accordance with the data of
JOHANSSON et al (7). The benign cases have been inserted
in figure 5 (right).
Tab. 4
Estrogen binding capacities in tissue samples of benign human breast
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The coefficient of variation (C. V.) of the determinations
of estrogen binding capacity was calculated to be ± 55%
for the category of "receptor negative' tumours (< 4,000
counts/min · g tissue) and to be ± 11% for the category
of tumours within the range of 8,000—20,000 counts/
min · g tissue. The large C. V. of the assays within the
first group may explain a few negative results (see fig. 5).
The binding of 3H-estradiol by the benign tumours
showing less than 4,000 counts/min · g tissue was
significantly suppressed by Upjohn 11,100 (t = 4.5, con-
fidence level 95%). The suppression by Upjohn 11,100
for the tumours within the category of 8,000—20,000
counts/min · g tissue however, was distinctly more
significant (t = 84.2, confidence level 95%). Thus the
tumours classified as 'receptor-negative' have a very low
binding capacity which is statistically discernible from
zero in spite of the large C. V. of the assay.
The above data on the significance of the suppression
indicate that the differentiation of tumours possessing an
estradiol binding capacity of less than 4,000 counts/
min · g tissue from those having an estradiol binding
capacity higher than 8,000 counts/min · g tissue has some
meaning. To test this differentiation, the group of
benign tumours and the malignant tumours in the
category 8,000—20,000 counts/min · g tissue, were in-
vestigated if their data follow different GAUSSIAN distri-
bution curves. The results are depicted in figure 6. If the
observed estrogen binding capacities were lying on one
straight line, the above discrimination would not have
a statistical meaning. From figure 6 it is evident that the
group characterised by an estrogen binding capacity less
than 4,000 counts/min · g tissue (left line) is distinctly
different from the group having higher estrogen binding
capacity. It is interesting to note that two benign
tumours considered from figure 5 as freceptor-positive'
belong to the group of malignant tumours with highly
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Discussion
The usefullness of tissue slices for the assay of estradiol
binding capacity of a tumour is limited since the time
lapse between operation and the assay should not exceed
24 hours (7).
Another approach is the density gradient technique
which is not practical as a routine. In addition the
detection of non specific binding, by albumin may give
problems since receptor bound estradiol may appear
in the same region as albumin bound estradiol (11, 12).
None of the above problems is encountered, if charcoal
incubation or electrophoresis is used to discriminate
against unspecifically bound estradiol. The first of these
techniques is most simple to perform routinely but two
points which need discussion are the specificity and the
clinical aspects of the present method. The mechanisms
of suppression of the amount of bound 3H-^estradiol by
Upjohn 11, 100 or excess unlabelled estradiol are diffe-
rent. JENSEN et al (1) were the first to demonstrate that
Upjohn 11, 100 inhibits the uptake and incorporation of
estradiol by target tissues like rat uterus or rat mammary
tumour. Part of these findings were confirmed by TERE-
NIUS (7) who also demonstrated that Upjohn 11, 100
inhibits the binding of estradiol in. tissue slices taken
from human mammary tumours. These studies in-
volved a restricted number of tumours (seven). The
results of the present study using homogenates give
additional support that Upjohn 11, 100 inhibits estrogen
binding by the receptor since Upjohn 11, 100 has an
effect on estradiol binding comparable with preheating
which denaturates the receptor (11, 12). Excess of un-
labelled estradiol competes with the labelled for all
binding sites which are saturable. Thus, sex hormone
binding globulin (SBG) which is a constituent of normal
serum even from post-menopausal women (13) may be
estimated using the suppressibility of bound 3H-estradiol
by excess of unlabelled estradiol. Since homogenates of
tumours contain serum proteins, sex hormone binding
globulin may be involved in the assay of the receptor
in breast tumour homogenates. In this respect it should
be noted that there is no evidence in the literature that
Upjohn 11,100 might interact with sex hormone binding
globulin. Diethylstilboestrol which is simpler structur-
ally, and, like Upjohn 11, 100, also has a double ring
system, does not bind sex hormone binding globulin (14).
We have found that Upjohn 11, 100, unlike dihydro-
testosterone, slightly reduces the binding of estradiol to
plasma from pregnant women which contains high levels
of sex hormone binding globulin (15). Preheating at
45— 50° C for one hour partly destroys the capacity of ·
sex hormone binding globulin to bind testosterone (13).
From these points, it may be concluded that if sex
hormone binding globulin interferes in the assays using
preheating or Upjohn 11,100 to discriminate for receptor
bound estradiol, the interference will be minor. It was
expected that with excess unlabelled estradiol a number
of false positive cases should be found as compared to the
other controls. Consideration of the data of table 3
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suggest that at least in the present study sex hormone
binding globulin has not been present in sufficient
amounts to be measured. It seems to us that for routine
practice the technique presented in this paper can be
restricted to the use of Upjohn 11, 100 as a competitor
to the receptor and the preincubation at 45° C as an
additional control. For a more refined study of any
occurrence of sex hormone binding globulin the
electrophoresis technique as developed by WAGNER (12)
seems the method of choice. Further work will be devoted
to this matter since we hope to improve the separation
of the fractions.
The data of figure 4 show a linear relation between the
amount of homogenate and the estradiol binding
capacity. SANBORN et al (16) have studied the behaviour
of the charcoal incubated and charcoal unincubated
estrogen receptor complex in a sucrose gradient. Their
results showed that a 10—15 minutes incubation as used
in the KORENMAN and DUKES technique was sufficient
to bind excess estradiol. We have found that changing
the incubation time from 5 to 25 minutes did not signi-
ficantly effect the results of the assay which is in agree-
ment with observations by TERENIUS (17). The present
method could therefore be considered to be quantitative
but the clinical significance of quantitative interpretation
of the result has still to be settled.
The results of the present study indicate that only some
human breast tumours contain receptors, which agrees
with earlier reports on in vivo binding of estradiol (3, 4),
and that only certain tumours bind estradiol in vitro
(6, 7, 8, 10). They are, however, in disagreement with
these reports concerning the given percentages of '
tumours having estradiol binding capacity. JOHANSSON
et al (8) and JENSEN et al (6) examined 51 and 31 tumours
and found that approximately 40 and 50% possessed
estrogen receptors, respectively. TERENIUS (7) and
KORENMAN and DUKES (10) studied a group of about
15 patients and found that 30% of the tumours bound
estradiol. Concerning the disagreement with the reports
which use homogenates (6, 10), it seems reasonable to
assume that the higher percentage of positive findings
in this study (about 70%) is related to our homogenisa-
tion technique which gives a maximum of certainty that
heat denaturation is avoided. During the preparation of
this paper a report of FEHERTY et al (18) appeared
describing an assay using low speed homogenisation
with large intervals of cooling. It is interesting to note
that these authors found estradiol binding in 37 out
of 53 tumours. We feel that these data support our view
that the choice of homogenisation technique is deter-
mined by the heat lability of .the receptor protein. The
differences of percentages with the reports using tumour
tissue slices may be related to number of specimens used
in the incubation and competition experiments which
may be to low to average out the heterogeneity of the
material. Another explanation would be that prior to the
binding to the receptor some factor is involved deter-
mining the uptake of the hormone through the cell wall.
This factor could influence the results in assays using
tissue slices.
In 1967 JENSEN et al (1) suggested that knowledge about
the presence of receptors in tumour tissue would make
it possible to predict the response of human breast cancer
to endocrine therapy. The reasoning was that tumours
with estradiol binding receptors are estrogen dependent
for their growth in analogy to estrogen responsive target
tissues in animals. Since, roughly speaking, a third of the
patients benefit from hormone therapy, a finding of 30%
(7) of receptor positive tumours was considered by
TERENIUS as a support for the above suggestion. The
present study, however, reveals about 70%, but it
should be noted that part of these tumours have medium
binding capacity. It may very well be that patients with
tumours possessing high estrogen binding capacity
would benefit from hormone therapy. This would imply
that quantitative interpretation is necessary. One ques-
tion to be solved is to which parameter (tissue weight or
tissue DNA, or tissue protein, etc) it is clinically prefer-
able to relate the estradiol binding capacity. Another
problem is the effect of endogeneous estrogen levels on
the measurements of specific estrogen binding capacity.
In fact, any assay method published so far measures
mainly latent estrogen binding capacity, since endo-
geneous estrogen is bound to the receptor so firmly that
the rate of exchange with the labelled estrogen during
incubation is low. For the present method an exchange of
about 50% of endogeneously bound estrogens could be
expected at the most (19). JOHANSSON et al (8) and
FEHERTY et al (18), using a shorter incubation time,
consider that their data show the effect of endogeneous
estrogens to be negligible. To gain more insight into
this problem and into the relation between the presence
of receptors and endocrine therapy, further studies
involving estrogen assays in blood and tumours are now
in progress. We feel that the present method, being
simple and suitable for routine application, could be
used in such studies.
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